Essai Clinique

Généré le 06 mai 2024 à partir de

Titre	Étude d'observation post-commercialisation visant à décrire la gestion et l'utilisation des ressources de soins de santé chez les patients atteints de leucémie lymphoïde chronique (LLC) à l'instauration du vénétoclax dans la pratique clinique courante
Protocole ID	P16-489 (DEVOTE)
ClinicalTrials.gov ID	NCT03310190
Type(s) de cancer	Leucémie lymphoïde chronique (LLC)
Phase	Autres
Médicament	venetoclax
Institution	CISSS DU BAS-SAINT-LAURENT HOPITAL REGIONAL DE RIMOUSKI 150 av. Rouleau, Rimouski, QC, G5L 5T1
Ville	Rimouski
Investigateur principal	Dre Marie-Pierre Bernard
Coordonnateur	Julie Levesque 418-724-3000 poste 8029
Statut	Fermé
But étude	A study to assess the real-life management and use of healthcare resources during the initiation of venetoclax in participants with chronic lymphocytic leukemia (CLL) with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.
Critères d'éligibilité	• Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study. • Has chronic lymphocytic leukemia (CLL) with deletion of the short arm of chromosome (17del[17p]) who have received at least 1 prior therapy, or CLL without del(17p) who have received at least one prior therapy and for whom there are no other available treatment options.
Critères d'exclusion	• Currently participating in an interventional study. • Using strong CYP3A inhibitors. • Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL. • Is pregnant or not using appropriate means of contraception.